Phase I study evaluating the systemic and mucosal safety and immunogenicity of a recombinant HIV-1 Gp 160 (MN/LAI) [HIV gp160 vaccine] administered by transmucosal (nasal or vaginal) routes, alone or formulated with DC-Chol, in HIV negative volunteers (ANRS VAC14)
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2005
At a glance
- Drugs HIV gp160 vaccine; HIV gp160 vaccine
- Indications HIV-1 infections
- Focus Adverse reactions
- 13 Dec 2005 New trial record.